Hepatitis A

Summary

It is spread through the faecal-oral route or when infected faecal matter enters the mouth.

Symptoms can be debilitating but most people infected with hepatitis A recover completely.

Once you have had hepatitis A you cannot get it again.

Vaccination against hepatitis A is available.

About the virus

Hepatitis A is an acute (short-term but quite severe) infection of the liver caused by the hepatitis A virus. The hepatitis A virus can survive in the environment on hands for several hours and in food kept at room temperature for considerably longer and is relatively resistant to detergents.

Hepatitis A occurs worldwide. In developing countries most people are infected during childhood due to poor sanitation. With good sanitation and hygiene in the developed world, most people now reach adulthood without being exposed to hepatitis A virus.

In Australia, there are approximately 300–500 cases of hepatitis A reported per year. The number of cases reported has been declining nationally since the late 1990s (DoHA 2006). In 2011 there were 144 diagnosed cases of hepatitis A in Australia (Kirby Institute; 2012).

The real number of hepatitis A infections is likely to be more than the number of infections reported. This is because many people with hepatitis A do not have obvious symptoms, do not go to the doctor and so are not tested for hepatitis A.

Up to 40% of people with hepatitis A have no identifiable risk factors for infection.

In Australia infection with hepatitis A is more likely in particular locations and amongst specific groups of people, including:

child day-care centres and pre-schools;

men who have sex with men;

injecting drug users;

residential facilities for the intellectually disabled; and

travellers to countries where the infection is common (Asia, Africa, South-Pacific, Central and South America).

Infection resulting from contaminated food or water, or an infected food handler is rare in Australia.

Infants and young children infected with hepatitis A will rarely show symptoms of infection and may appear quite well, or have only mild symptoms. The majority of adults will show symptoms.

Symptoms of Hepatitis A

The duration of the illness varies but most people feel better and their Liver Function Tests (LFTs) begin to normalise a month after the onset of infection. Hepatitis A infection never causes a chronic (long-term) infection.

Death because of hepatitis A infection is very rare. The likelihood of severe disease or death resulting from hepatitis A infection is much greater in people with pre-existing liver damage, including people with chronic liver disease due to hepatitis B or C, and people over 50 years of age.

Transmission of Hepatitis A

Hepatitis A is most commonly spread by the faecal-oral route. Faecal-oral transmission of the hepatitis A virus may occur when anything that has been contaminated with infected faeces is put in the mouth, for example:

Food, liquid or eating utensils can transmit the virus from an infected person.

Touching nappies, linen and towels soiled with the faeces of an infectious person.

Direct contact (including sexual) with an infectious person.

Testing for Hepatitis A

The incubation period (time between exposure to the virus and the development of symptoms) varies between 15 and 50 days, with an average of 30 days. Hepatitis A virus is excreted for up to two weeks before the onset of symptoms. Therefore, people with hepatitis A should be considered infectious for a week after the onset of jaundice.

Hepatitis A is diagnosed by a blood test. The detection of IgM hepatitis A antibodies (anti-HAV IgM) confirms recent infection. These antibodies are present for three to six months after infection. The detection of IgG hepatitis A antibodies (anti-HAV IgG) indicates past infection and immunity against hepatitis A infection.

There is no medical treatment available for hepatitis A. The symptoms of hepatitis A may be relieved by rest and adequate fluid intake. Medications should be limited to those considered essential and alcohol should be avoided.Treatment

Prevention

To avoid the transmission of hepatitis A:

Always wash hands thoroughly after going to the toilet, before preparing and eating food, after handling soiled linen e.g. nappies.

When travelling in regions with poor sanitation, drink bottled water and avoid eating food that has been cleaned or prepared using contaminated water.

In a natural disaster, listen to warnings about contaminated drinking water and follow any instructions issued by the relevant authorities.

Consider being vaccinated (see below for more details).

A vaccine is available to protect against hepatitis A infection in people two years of age and older. There are currently five hepatitis A vaccines and two combined hepatitis A/hepatitis B vaccines registered for use in Australia. The vaccines are made from inactive hepatitis A virus. The body reacts with the inactive virus to produce antibodies that protect against infection. Clinical trials have shown that the hepatitis A vaccine is effective in preventing infection in about 95% of people.

Vaccination

Protection begins within 14-21 days after the first dose of the vaccine. A second dose of vaccine is required for long-term protection. The duration of immunity following vaccination is not certain, however, it appears to be at least 10 years, probably longer.

All Aboriginal and Torres Strait Islander children between 18 months and six years of age in north Queensland;

Workers in rural and remote Indigenous communities;

Child day-care and pre-school personnel;

The intellectually disabled and their carers;

Healthcare workers employed in pediatric wards, intensive care units and emergency departments that provide for substantial populations of Aboriginal and Torres Strait Islander children and nursing and medical staff on rural and remote Indigenous communities;

Sewage workers;

Men who have sex with men;

Injecting drug users;

Patients with chronic liver disease of any aetiology; and

Patients with haemophilia who may receive pooled plasma concentrates.

People at risk of exposure to both hepatitis A and hepatitis B, particularly healthcare workers, people who inject drugs, men who have sex with men, travellers and long-term visitors to developing countries, should consider receiving the combined hepatitis A/hepatitis B vaccine.

It is recommended that people with hepatitis C are vaccinated against both hepatitis A and hepatitis B.

The most common adverse event following administration of the hepatitis A vaccine is mild local pain at the site of injection, but this should last only a short time.

Pregnant women should delay being immunised against hepatitis A until after the pregnancy, unless there is a substantial risk of them being exposed to the virus.

People who are in close household or sexual contact with someone with hepatitis A should received normal human immunoglobulin within two weeks of exposure.

Administration of the immunoglobulin will prevent infection for approximately six weeks.

Hepatitis A vaccine can be given at the same time as the immunoglobulin.

Hepatitis Australia

Hepatitis
Australia is the national peak body representing the interests of Australians
living with, or at risk, of viral hepatitis.
Our members are the eight state and territory hepatitis organisations.
Through national leadership, advocacy, and strong partnerships our mission is
to ensure effective action on hepatitis B and hepatitis C to meet the needs of
all Australians.

LATEST NEWS

Curative treatment uptake for chronic hepatitis C (CHC) is generally at its lowest in local areas where prevalence of the virus is at its highest, according to the inaugural Hepatitis C Mapping Project National Report 2016 recently launched in Melbourne.

Australia will not achieve the goal of eradicating hepatitis C without further action to ensure patients are identified and treated.

Speaking with PharmaDispatch following her appointment as president of Hepatitis Australia, Felicity McNeill PSM, said so much positive work has been done, with thousands of people cured, but all stakeholders must come together to address the fact treatment rates are in decline.

Someone very familiar to the pharmaceutical sector has been appointed president of Hepatitis Australia. Felicity McNeill PSM, who for almost five years served as first assistant secretary of the Pharmaceutical Benefits Division, has been appointed to the part-time role of president of the national peak body focussed on representing Australians living with hepatitis B and C.

After three days of discussing, debating and formulating solutions together, the World Hepatitis Summit 2017 drew to a close on Friday. Over 900 delegates from 110 countries descended on São Paulo, Brazil all armed with one goal: the elimination of viral hepatitis. At the event, double the size of the inaugural World Hepatitis Summit 2015, important steps were made to reach this goal by 2030.

Hepatitis Australia’s Acting CEO Kevin Marriott told PharmaDispatch the organisation is concerned over the recent fall in [hepatitis C treatment] uptake and it is now working to ensure as many people as possible access treatment.

Responding to the Kirby Institute’s report, Hepatitis Australia’s Acting CEO Kevin Marriott said that Australia needs to capitalise on this early success to ensure all Australians impacted by viral hepatitis have access to effective treatment and care.

Following an energetic dinner where delegates showed off their samba moves, the second day of the World Hepatitis Summit was dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity" - “the what and the how” of elimination.